Fourth Ring Pharmaceuticals: The first subject has been enrolled in the Phase III clinical trial of Anlazole Sodium for the new indication of reflux esophagitis.

Circular Pharmaceutical Announcement: Xuanzhu Biological Technology Co., Ltd., a non-wholly owned subsidiary of the group, has completed the enrollment of the first subject in the Phase III clinical trial of Annerlazole Sodium enteric-coated tablets, a type 1 innovative drug independently developed for the treatment of gastroesophageal reflux disease. The study aims to comprehensively evaluate the efficacy and long-term safety of Annerlazole Sodium enteric-coated tablets in the treatment of gastroesophageal reflux disease, providing key data support for the approval of this indication. Annerlazole Sodium enteric-coated tablets is currently the first and only PPI in China that is completely independently developed, and it is also the only innovative PPI in China. According to Zhushi Consulting data, the number of people suffering from gastroesophageal reflux disease in China is estimated to be about 38.3 million in 2024, and is expected to increase to 42.4 million by 2032.